Beta Bionics (BBNX) has opened Q1 2026 with revenue of US$27.6 million and a basic EPS loss of US$0.49, alongside a trailing twelve month revenue base of US$110.2 million and a basic EPS loss of US$1.51. Over recent quarters the company has seen revenue move from US$17.6 million in Q1 2025 to US$32.1 million in Q4 2025 and then to US$27.6 million in Q1 2026, while quarterly basic EPS losses ranged between US$0.30 and US$0.93 over that period. This context may lead investors to focus on how effectively those revenues are being converted into potential future margins.

See our full analysis for Beta Bionics.

With the headline numbers in place, the next step is to see how this earnings profile lines up against the key market narratives around growth, risk, and the path to stronger margins.

Losses Stay Heavy Around US$66 Million

• On a trailing twelve month basis, Beta Bionics reported US$110.2 million in revenue and a net loss of US$66.4 million, with trailing basic EPS at a loss of US$1.51.
• Bears argue that continued loss growth of about 9% per year over the last five years and forecasts for at least three more years of losses make the current model hard to justify, and the latest numbers give them support.
  • The Q1 2026 net loss of US$21.9 million compares with losses in the US$13.5 million to US$28.7 million range over the last five reported quarters, which fits the picture of a still loss making business.
  • With the share price at US$12.20 and no forecast path to profitability in the next three years, skeptics highlight that any thesis here leans heavily on future margin improvement that is not yet visible in reported EPS.

Stay on top of how Q1’s loss profile fits the cautious case by reading how skeptics frame the downside in the 🐻 Beta Bionics Bear Case.

Revenue Momentum vs 25.8% Growth Forecast

• Over the last five reported quarters, revenue ranged from US$17.6 million to US$32.1 million per quarter, feeding into trailing twelve month revenue of US$110.2 million alongside a forecast for roughly 25.8% annual revenue growth, which is higher than the cited 10.9% forecast for the broader US market.
• Bullish investors see the faster 25.8% revenue growth forecast as central to their thesis, and the recent revenue base gives them building blocks to point to even if profitability is not yet in place.
  • The move from US$69.8 million in trailing revenue at the start of 2025 to US$110.2 million by Q1 2026 shows that more revenue is flowing through the business, which bullish views link to products like the iLet system and growing recurring supply sales described in their narrative.
  • At the same time, trailing net losses of US$66.4 million and forecasts for continued unprofitability test the bullish claim that top line growth alone can support the story, since those losses still absorb a large share of every revenue dollar.

If you want to see how revenue growth, margins, and product rollout all fit into the optimistic case, check out the 🐂 Beta Bionics Bull Case.

Mixed Valuation Signals at 4.9x P/S

• The shares trade on a P/S of 4.9x, above the US Medical Equipment industry average of 2.8x but below a peer group average of 9.7x, while the current price of US$12.20 sits against an analyst target level of US$21.36 and a DCF fair value of US$28.47.
• Analysts who lean toward a balanced view see both risk and reward in this set up, and the numbers highlight why sentiment is not one sided.
  • The higher P/S than the broader industry, together with revenue forecasts above the 10.9% market growth rate, suggests the market is already assigning a premium to Beta Bionics’ growth profile despite ongoing losses.
  • On the other hand, the trailing net loss of US$66.4 million and expectations for at least three more years of unprofitability underscore why the P/S multiple still sits below the 9.7x peer average and why some investors may be cautious about paying closer to the US$21.36 target level.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Beta Bionics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Feeling that this story could break either way given the mix of risks and rewards investors are weighing right now? Act while the details are fresh and test the numbers against your own expectations by reviewing the 1 key reward and 2 important warning signs.

See What Else Is Out There

Beta Bionics carries sizeable trailing losses of US$66.4 million, a basic EPS loss of US$1.51, and expectations for several more years without profitability.

If that level of uncertainty feels too high, shift your attention to companies screened for more resilient profiles by checking out 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.